Clinical progress for the EGFR-TKI combined with radiotherapy in non-small cell lung cancer
10.3760/cma.j.issn.1008-1372.2016.06.004
- VernacularTitle:EGFR-TKI联合放疗治疗非小细胞肺癌研究进展
- Author:
Juan LIN
;
Shuiyun HAN
;
Yaping XU
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small-cell lung/TH;
Receptor,epidermal growth factor/AI/TU;
Protein-tyrosine kinases/AI/TU;
Radiotherapy;
Review
- From:
Journal of Chinese Physician
2016;18(6):813-817
- CountryChina
- Language:Chinese
-
Abstract:
At present,the treatment for non-small cell lung cancer (NSCLC) consists of surgery,radiation,chemotherapy,targeted therapy,etc.The epidermal growth factor receptor (EGFR) gene mutation opened a new era of individualized treatment.Multidisciplinary treatment come next after the combination of different treatment approaches,and the modality of targeted therapy like epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in combination with radiation was included.The present work reviews clinical progress for the EGFR-TKI combined with radiotherapy in advanced NSCLC.